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Abstract
Aldosterone is a mineralocorticoid hormone which plays a pivotal role in water and electrolytes balance. Moreover, 
aldosterone exerts a deleterious influence on the cardiovascular system and kidneys. In this review, we wanted to 
show mechanisms of aldosterone related organ damage, the role of aldosterone in kidney diseases, hypertension and 
therapeutic benefits related with aldosterone receptors blockade.
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Introduction
The renin–angiotensin–aldosterone system (RAAs) plays 
a key role in the pathogenesis of hypertension, kidney 
disease and congestive heart failure (CHF). Research 
on its individual links has been carried out for many 
years. One of the elements of this system that still 
raises a lot of controversies is aldosterone. This miner-
alocorticoid hormone was discovered and described in 
1953 by Simpson, Tait and Wetstain. In 1955, dr. Je-
rome Conn described the case of a woman with severe 
hypertension, hypokalemia and proteinuria caused by 
aldosterone-producing adenoma. Many studies from 
the nineties last century provided proof that aldo-
sterone constituted a factor responsible for myocar-
dial fibrosis and progression of chronic kidney disease 
(CKD). Subsequent studies in which a well-known al-
dosterone antagonist spironolactone was used, showed 
that this agent added to the classical RAA blockers 
i.e. losartan and enalapril reduces both proteinuria, 
blood pressure and decreases left ventricular hyper-
trophy (LVH) [1, 2]. A number of publications ad-
dressed the benefits of blocking the mineralocorticoid 
receptor in patients with CHF, kidney diseases and 
resistant hypertension [3]. Mineralocorticoid receptor 
antagonists have enjoyed a well-established position 
in pharmacotherapy since the publishing of results of 
two major clinical trials: the RALES trial (1999) (in 
which spironolactone was used) and the EPHESUS 
trial (2003) (in which eplerenone was used) which 
proved that these mineralocorticoid receptors antago-
nists had a beneficial effect on decreasing mortality 
rates in CHF patients [4, 5].
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Aldosterone — synthesis and effects
Aldosterone is the strongest mineralocorticoid hor-
mone produced both in the zona glomerulosa of 
the adrenal gland cortex, it is also synthesized extra-
adrenally in endothelial and vascular smooth muscle 
cells (VSMC), as well as in the heart and kidneys. 
Aldosterone demonstrates activity through protein 
mineralocorticoid receptors type 1 in epithelial cells 
of the renal tubules, colon, salivary glands, sweat 
glands, rectal mucosa and urinary bladder. It also 
affects non-epithelial cells of the central nervous sys-
tem, as well as cardiomyocytes and VSMC. It serves 
as an important regulator of the water-electrolyte 
balance, thus contributing to maintaining the wa-
ter-electrolyte homeostasis. Acting at the level of 
distal and collecting tubules, it regulates the Na+/
K+-ATPase-mediated reverse transport of sodium and 
water and amplifies the inward cellular transport of 
potassium. In patients with CKD, whose significant 
clinical problem is the common occurrence of hyper-
kalemia, aldosterone intensifies the tubular secretion 
of potassium, enhances the processes of transmin-
eralization, and increases the extrarenal disposal of 
potassium with stool. Factors affecting the synthesis 
and regulation of aldosterone secretion are angio-
tensin II, endothelin, ACTH, hyperkalemia (major 
regulatory factor in patients with kidney failure) and 
hypovolemia [6, 7].
Classical effects of aldosterone are associated with 
its influence on the water-electrolyte balance. It 
causes hypervolemia, hypokalemia, hypomagnese-
mia, hypochloremia, and metabolic alkalosis. More-
over, aldosterone exerts multidirectional pleiotropic 
effects falling far beyond the classical scope. It ag-
gravates cardiovascular system fibrosis, fibrosis of 
renal interstitial tissue, vasoconstriction, endothelial 
dysfunction, affects and the hemostatic system and 
enhances inflammation [7]. These effects contribute 
to the progression of cardiovascular and renal dam-
age. They are particularly severe in the case of high 
sodium consumption. Effects resulting from the ex-
cess of aldosterone are presented in Table I.
Aldosterone and cardiovascular damage 
in patients with CKD
Cardiovascular diseases are the main cause of in-
creased mortality rates in CKD patients. This fact 
is well-known since the 1970s when first reports 
concerning this matter were published by Linder et 
al. [8]. Aggravation of atherosclerosis, also common 
in younger CKD patients results in a 10 to 12-fold 
higher risk of acute coronary episodes and death as 
compared to the general population. The more fre-
quent occurrence of cardiovascular diseases (CVD) 
is a result of the influence of both traditional and 
non-traditional risk factors i.e. peculiar for kidney 
disease, including anaemia, disturbances in calcium-
phosphate management (CKD-MBD), vessels cal-
cification, the presence of an arteriovenous fistula, 
hyperhomocysteinemia and others [9]. 
Aldosterone excess and its local synthesis is a po-
tent stimulator of myocardial fibrosis in CKD pa-
tients with coexisting CHF. Increased local synthesis 
of collagen type I (PINP) and III (PIIINP) was ob-
served in this population. This applies particularly 
to patients after myocardial infarction (MI) who 
present post-infarction heart failure, in whom aldo-
sterone plays a crucial role in the post-infarction left 
ventricle (LV) remodelling [10]. Aldosterone related 
cardiac fibrosis causes its indirect proarrhythmic ef-
fects. Aldosterone also contributes to the impairment 
of insulin secretion. Increased levels of glucose in 
diabetic patients aggravate the aldosterone-induced 
processes of cardiomyocytes hypertrophy [11].
Moreover, excess aldosterone affects LVH in pa-
tients with hypertension and CKD both on con-
servative and renal replacement therapy treatment 
(RRT) [12]. It also contributes to the aggravation of 
endothelial damage, inhibition of nitric oxide syn-
thase (iNOS) activity, and impairment of endothe-
lium-dependent vasodilation [13]. Apart from being 
involved in cardiac remodelling, aldosterone also 
plays a role in the process of vascular remodelling, 
leading to increased arterial stiffness related to the 
accumulation of fibronectin [14]. 
The deleterious effects of aldosterone excess are 
also associated with sodium retention, hypokalemia, 
Table I. Aldosterone and its multidirectional effects
Aldosterone — classical effects
Influence on the water-electrolyte balance (sodium and water  
retention, hypokalemia, hypochloremia, hypomagnesemia, metabolic 
alkalosis)
Intravascular volume increase and participation in the regulation  
of arterial blood pressure
Aldosterone — pleiotropic effects
Synthesis of collagen, TGF-b activation, aggravation of heart, 
vessels and kidney interstitial fibrosis
Influence on the hemostatic system, PAI-1 activation
Endothelial dysfunction.
Proinflammatory action and immunomodulation action
Effect on bone metabolism
Aggravation of oxidative stress
Effect on the concentration of lipids
Kidney damage — mesangial cells proliferation and podocytes  
damage
TGF-b — transforming growth factor b; PAI-1 — plasminogen activator inhibitor-1
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influence on blood pressure, impairment of the func-
tion of baroreceptors, and increased adrenergic activ-
ity in patients with CHF [15]. Heart and vascular 
damage induced by aldosterone excess cause the local 
inflammatory response, the activation of various cy-
tokines and inflammatory mediators such as MCP-1, 
COX-2, osteopontin [16]. Moreover, aldosterone ag-
gravates oxidative stress and impaired tissue insulin 
sensitivity of the vascular wall. It contributes to the 
acceleration of atherosclerosis. It is also worth to 
mention about the role of aldosterone in the metabo-
lism of bone tissue and its influence on the immune 
system. According to the many of aldosterone action, 
aldosterone antagonists usage is a part of cardio- and 
angioprotection in CKD patients. 
Role of aldosterone in the progression 
of chronic kidney disease (CKD)
Inhibiting the progression of kidney diseases associ-
ated with the use of aldosterone receptor antagonists 
is a consequence of the effects of those drugs on 
numerous components of pathophysiological pro-
cesses responsible for progressive and irreversible re-
nal damage. The only undeniably significant element 
inhibiting the process of renal damage is the reduc-
tion of blood pressure. Hypertension is a modifi-
able factor undoubtedly leading to increased urinary 
protein excretion and proteinuria-related glomerular 
filtration impairment. It must also be emphasized 
that the nephroprotective effect of those drugs, that 
is inhibiting the progression of kidney disease, seems 
to be independent of the reduction of blood pres-
sure, which has been proved in a number of clinical 
trials [17, 18]. It has recently been stressed that this 
beneficial effect might be a consequence of the non-
genomic action of these drugs, which is independent 
of the direct action of aldosterone antagonists on 
its nuclear receptor. There is extensive data indicat-
ing that the nongenomic action of this drug group 
takes place through the membrane receptor [19]. 
The nephroprotective effects of aldosterone receptor 
antagonists, also resulting from their influence on 
the membrane receptor, might be strongly associated 
with their beneficial effects on endothelial function 
[20].
The role of aldosterone in the process of kid-
ney damage should be investigated in the context 
of systemic effects, as well as local effects within the 
organ itself. In a study of biopsy specimens obtained 
from patients with primary and secondary glomeru-
lopathies, it was found that mRNA expression for 
aldosterone receptors increased proportionally to 
the levels of urinary protein excretion. Moreover, in 
patients with the highest albumin excretion rates, 
increased mRNA expression was also found within 
the interstitium, while in patients whose protein 
excretion rates were lower, mRNA expression was 
mainly associated with the area of distal and collect-
ing tubules. In the context, it should be noted that 
along with the increase in mRNA expression for 
the aldosterone receptor in individual fragments of 
biopsy specimens, a proportional increase in mRNA 
expression was revealed for MCP-1 and TGFb-1, 
which are key factors influencing the development 
of renal tubulointerstitial fibrosis. The increase in 
mRNA expression for the aldosterone receptor was 
a local response to nephron exposure to the level of 
proteinuria and was not determined by the serum 
concentration of aldosterone [21]. Another mecha-
nism responsible for the occurrence of proteinuria is 
podocyte injury associated with the overexpression of 
aldosterone receptors within the glomerulus. How-
ever, increased aldosterone receptor expression in 
podocytes is independent of the serum concentration 
of aldosterone [22, 23]. Notwithstanding the above-
mentioned data, there is a lot of evidence indicating 
that the efficiency of aldosterone receptor antagonists 
administration in proteinuric patients is also affected 
by the degree of aldosteronemia. This can be inferred 
from data revealing that a decrease in protein excre-
tion rates resulting from the use of spironolactone 
remains in simple correlation with the serum con-
centration of aldosterone [24].
The interest in possible applications of aldosterone 
antagonists in the field of nephroprotection inspires 
researchers to undertake further studies, including 
a large proportion of clinical trials. Regardless of the 
acknowledged risk associated with this therapy (such 
as hyperkalemia), drugs from this group have been 
more and more commonly used in the treatment of 
CKD [25].
Therapeutic possibilities associated 
with mineralocorticoid receptor 
blockade in CKD and hypertension 
patients
The use of angiotensin-converting enzyme inhibi-
tors (ACE-I) and angiotensin II receptor blockers 
(ARB) in clinical practice has become a commonly 
accepted form of treatment of cardiovascular diseases 
(CVD) and kidney diseases accompanied by pro-
teinuria or renal function impairment. In numerous 
studies published also by Polish authors, there had 
been shown that these drugs inhibit the progression 
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of CKD into the end stage phase and reduce protein-
uria [26]. A decrease in the synthesis of aldosterone 
is often observed in the first months of their admin-
istration, however, due to the so-called aldosterone 
escape phenomenon, their prolonged administration 
does not lead to a further decrease in aldosterone 
synthesis. It seems that this problem may be observed 
in approximately 30–50% of patients treated with 
ACE-I/ARB [27, 28]. Complete control over the 
RAA system requires the supplementary drugs from 
the group of mineralocorticoid receptor antagonists 
(MRAs). In clinical practice, the most commonly 
used ones are spironolactone and eplerenone. The 
latter is more selective for the mineralocorticoid re-
ceptor and demonstrates fewer adverse effects related 
to its influence on hormonal balance (lower affinity 
for androgen and progesterone receptors).
Recently, a new mineralocorticoid receptor an-
tagonist (MRA) — finerenone has been introduced 
in treatment. It is a nonsteroidal drug which does not 
induce hyperkalemia [29]. The above mentioned 
MRA has been successfully used in CKD patients 
both on conservative treatment and on RRT. A meta-
analysis of 18 randomized clinical trials in 1786 dia-
betic nephropathy patients in whose standard thera-
py with ACE-Is or ARBs use was supplemented with 
the administration of MRA, demonstrated a benefi-
cial effect of this combination and decrease in the 
urinary albumin excretion rate, albumin/creatinine 
ratio (ACR), and blood pressure. There was no im-
provement in the glomerular filtration rate (GFR). 
An increased risk of hyperkalemia was observed [30]. 
Edwards et al. in CRIB-II study found that 10 weeks 
spironolactone treatment added to ACE-I or ARB 
caused reduction of the left ventricular mass index 
(LVMI) in non-diabetic CKD stage 2 and 3 patients 
[31]. Currently conducted BARACK-D trial (Bene-
fits of Aldosterone Receptor Antagonism in Chronic 
Kidney Disease) in 2616 patients with stage 3b CKD 
will compare the efficacy of spironolactone 25 mg 
once daily in addition to routine care (ACE-I/ARB) 
on mortality and cardiovascular outcomes versus 
routine care alone [32]. Combined treatment with 
ACE-Is/ARBs and aldosterone antagonist is possible 
in CKD patients, but it requires attention and a fre-
quent potassium level control. Practically speaking, it 
would be inadvisable to start treatment with MRA in 
CKD patients and eGFR < 30 mL/min or serum 
potassium level > 5.0 mmol/L. The risk of hyperka-
lemia related to the treatment significantly limits 
wider aldosterone antagonists use in CKD patients. 
It is worth to mention that a new pharmacological 
agent is now available to reduce hyperkalemia in 
CKD. Patiromer is a novel oral potassium binder 
indicated for hyperkalemia treatment in CKD pa-
tients on conservative treatment. The initial dose is 
8.4 g p.o. daily and it may be adjusted based on the 
potassium level up to 25.2 g daily. Patiromer added 
on standard treatment may facilitate aldosterone re-
ceptor antagonist introduction to therapy with other 
RAA inhibitors [33]. Advantages of the administra-
tion of aldosterone antagonists in the improvement 
of heart and vascular function have also been de-
scribed in dialysis patients [34]. Nitta et al. in a group 
of hemodialyzed patients, demonstrated positive ef-
fects of spironolactone on the inhibition of vascular 
calcification. He indicated that this effect was associ-
ated with a decrease of osteopontin expression in the 
vascular wall [35]. In our own study, conducted in 
a group of 22 peritoneal dialysis patients, an in-
creased plasma concentration of osteopontin after 12 
months of spironolactone treatment in a dose of 50 
mg daily was demonstrated. This effect can be con-
sidered beneficial because osteopontin besides its 
other actions is also considered to be a potent in-
hibitor of vessels calcification. There was no hyperka-
liemia during spironolactone administration [36]. 
Vukusich et al. in non-diabetic, hemodialyzed CKD 
patients demonstrated a beneficial effect of 2-year 
spironolactone administration 3 times a week at a dai-
ly dose of 50 mg for stabilization and even a reduc-
tion of the IMT complex thickness of carotid arteries 
[37]. The currently conducted STOP-CKD study in 
the population of CKD stage 3 patients in general 
practitioners (GP) care will show the influence of low 
doses of spironolactone on the reduction of arterial 
stiffness [38]. As it was mentioned above aldosterone 
antagonists administration is related to hyperkalemia 
risk. Chua et al performed a meta-analysis of 6 ran-
domized clinical trials in 154 hemodialyzed patients. 
They focused on the safety of spironolactone use in 
an aspect of hyperkalemia. The authors concluded 
that spironolactone seems to be safe in a short-term 
therapy. Strict potassium control is mandatory [39]. 
In DOHAS study 309 hemodialyzed patients were 
randomized to either placebo group or spironolac-
tone group and treated with 25 mg of spironolactone 
daily for3 years. In patients treated with spironolac-
tone, there was a statistically significant reduction of 
risk of death or cardiovascular hospitalization or 
death of general reasons in comparison to the place-
bo group. The incidence of life-threateninghyperka-
lemia was (potassium level > 6.5 mmol/L) 1.9% and 
gynecomastia occurred in 10% of the spironolactone 
patients [40]. The future perspective of spironolac-
tone treatment in hemodialyzed patients will be 
available soon as a result of another new study — AL-
CHEMIST study (Aldosterone Antagonist Chronic 
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Hemodialysis Interventional Survival Trial, ALCHE-
MIST) [41]. Moreover, in many studies benefits of 
aldosterone antagonists in peritoneal dialysis patients 
were confirmed. These both are a description of indi-
vidual case reports and randomized trials involving 
larger groups of patients. Hausmann et al. described 
an improvement in cardiac function manifested by 
an increase of ejection fraction from 32% to 46% in 
a patient receiving peritoneal dialysis treatment and 
spironolactone at a dose of 25 mg/day administered 
for 10 months [42]. Ito et al. in 2014 published the 
results of his study of 158 peritoneal dialysis patients. 
The combined treatment with ACE-I or ARB and 
spironolactone at a dose of 25 mg per day caused 
a significant improvement in left ventricular ejection 
fraction after 2 years of treatment compared to the 
control group. Left ventricular mass reduction 
(LVMI) was found after 6 months of therapy. There 
were no significant changes in risk of death [43]. The 
excess of aldosterone in peritoneal dialysis patients 
aggravates cardiovascular damage and contributes to 
the progressive failure of the peritoneal membrane. 
This may be related with accelerated fibrosis of the 
peritoneal membrane. Kolesnyk et al. showed a ben-
eficial effect of ARB treatment in halting the progres-
sion of the peritoneal membrane sclerosis and calci-
fication [44]. Vazquez-Rangel et al. in a group of 9 
patients on peritoneal dialysis treated with spirono-
lactone at a dose of 25 mg observed in histopatho-
logical evaluation of peritoneal membrane specimens 
reduction in severity of inflammation and collagen 
accumulation [45]. It is worth to mention that aldo-
sterone antagonists treatment in patients receiving 
peritoneal dialysis seems to be safe, because dialysis 
fluid does not contain potassium and the risk of life-
threatening hyperkalemia is significantly diminished. 
Aldosterone antagonists have a well-established posi-
tion in the treatment of secondary hypertension as-
sociated with primary hyperaldosteronism (prepara-
tion for a surgical procedure in adrenocortical adeno-
ma or unilateral adrenocortical hyperplasia, long-
term treatment in patients with primary hyperaldo-
steronism resulting from bilateral adrenal hyperpla-
sia) [46]. It should also be mentioned that aldoste-
rone antagonists have been demonstrated to have 
beneficial effects in the treatment of resistant hyper-
tension i.e. a clinical situation in which, despite life-
style modifications and treatment with 3 antihyper-
tensive drugs in optimal doses, including a diuretic, 
optimal blood pressure control is unattainable. Many 
previously published studies had proved the useful-
ness of aldosterone antagonists in patients with resis-
tant hypertension and the effectiveness of this group 
of drugs in the reduction of both systolic and dia-
stolic blood pressure. Advantages of aldosterone an-
tagonists use in the treatment of resistant hyperten-
sion had been shown in individuals with visceral 
obesity or obstructive sleep apnea syndrome (OSAS). 
It was also described that a large proportion of cases 
(approximately 23–25%) of primary hyperaldoste-
ronism are also found in patients with refractory 
hypertension [47, 48]. In obese patients with hyper-
tension, an elevated serum aldosterone level was ob-
served in comparison to patients with normal body 
weight and without hypertension. It may result from 
increased production of linoleic acid (EKODE) in 
adipocytes of obese patients. Linoleic acid has been 
shown to stimulate the secretion of aldosterone in 
the adrenal cortex [49]. There also have been demon-
strated interactions between parathyroid hormone 
(PTH) and aldosterone. PTH increases aldosterone 
secretion by affecting the RAA system. Both hor-
mones have a markedly adverse effect on the cardio-
vascular system [50]. The strong position of spirono-
lactone was recently confirmed in the completed 
randomized trial — Pathway-2. This study has shown 
that spironolactone was the most effective drug, 
more effective than doxazosin or bisoprolol as an 
add-on drug for treatment of really resistant hyper-
tension [51]. 
In conclusion, aldosterone excess through its 
metabolic effects, intensification of vasoconstriction, 
inflammation or fibrosis is undoubtedly a factor 
responsible for cardiovascular system damage and 
progression of CKD. Hence, it is of utmost impor-
tance to reduce its effects and to use aldosterone 
antagonists extensively in selected groups of patients. 
Bolignano et al. in the meta-analysis (published in 
2014) of studies with aldosterone antagonists added 
on ACE-I/ARB treatment found that these agents 
may cause a decrease of proteinuria and blood pres-
sure but their influence on cardiovascular mortality is 
rather questionable. Despite that statement currently 
conducted interventional studies will show final ben-
efits of these agents in kidney disease patients [52]. 
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